India's Leading Cancer Testing Company
Caris Life Sciences
Caris Molecular Intelligence
DIFFERENT TESTS FOR DIFFERENT CASES
DISCUSS YOUR CASE
Lack of Tissue for Testing
Patient with Non-Small Cell Lung Cancer stage 4 undergoing Chemotherapy. Limited tissue available for testing.
PositiveSelect Ultimate test recommended by the treating doctor. Test performed entirely through liquid biopsy (blood).
Testing revealed the patient has an EGFR exon 21 mutation. Treatment recommendations are made.
The doctor changed the treatment to Osmeritinib and the patient responded well.
Deciding on Chemotherapy
Patient with early-stage breast cancer [ER and PR = positive and Her2 = negative].
Patient undergoes mastectomy to remove tumor.
Doctor recommends EndoPredict. Results show the patient is in the low-risk group and can safely avoid chemotherapy.
Month 3-15 Years
Patient and doctor opt out of chemotherapy and successfully treatment with hormonal therapy alone for several years. Patient does not relapse.
Patient with stage 4 pancreatic cancer shows no response to first line chemotherapy.
Doctor and patient opt for Caris Molecular Intelligence testing to get a complete view of available treatment options and consultation with a Caris expert.
Detected with KRAS mutation and deficiency in Mismatch repair system so patient was prescribed Trametinib and Pembrolizumab as a treatment option.
Treatment options are successful and the patient’s cancer goes into remission.
When Standard of Care is Exhausted
Triple-negative breast cancer patient whose chemotherapy treatment is not working and the patient is progressing.
PositiveSelect Ultimate recommended by the treating doctor as standard of care treatments from guidelines have failed.
Detected with germline BRCA1 mutation and somatic PIK3CA mutation. Multiple therapy options recommended.
In consultation with the treating doctor and Positive Bioscience’s experts the next few treatment lines are carefully planned. Patient responds to therapies recommended.
First-line Treatment Failure
Patient with Non-Small Cell Lung cancer
No mutation in EGFR, ALK, ROS1 and PD-L1 and patient progressing on first line systemic therapy.
PositiveSelect Plus revealed high Tumor Mutation Burden (TMB). Recommendations made based on treatment guidelines.
Treatment changed to Nivolumab, an immunotherapy, and the patient response exceeds the treating doctor’s expectation.
Sign Up for Insights